| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KLK14 |
| Uniprot No | Q9P0G3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 41-267aa |
| 氨基酸序列 | IIGGHTCTRS SQPWQAALLA GPRRRFLCGG ALLSGQWVIT AAHCGRPILQ VALGKHNLRR WEATQQVLRV VRQVTHPNYN SRTHDNDLML LQLQQPARIG RAVRPIEVTQ ACASPGTSCR VSGWGTISSP IARYPASLQC VNINISPDEV CQKAYPRTIT PGMVCAGVPQ GGKDSCQGDS GGPLVCRGQL QGLVSWGMER CALPGYPGVY TNLCKYRSWI EETMRDK |
| 预测分子量 | 29,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与KLK14重组蛋白相关的3篇文献摘要示例(文献信息为模拟虚构，供参考)：
1. **文献名称**: *Recombinant expression and functional characterization of KLK14 in prostate cancer progression*
**作者**: Smith A et al.
**摘要**: 本研究通过大肠杆菌系统成功表达并纯化重组KLK14蛋白，证实其在前列腺癌细胞外基质降解中的活性，揭示了KLK14通过激活蛋白酶激活受体(PARs)促进肿瘤侵袭的分子机制。
2. **文献名称**: *KLK14 as a modulator of inflammation: Insights from recombinant protein-based assays*
**作者**: Chen L et al.
**摘要**: 利用哺乳动物细胞表达的重组KLK14蛋白，研究发现其能够切割炎症相关激肽原，释放缓激肽类似物，提示KLK14在炎症反应和血管通透性调节中的潜在作用。
3. **文献名称**: *Development of a KLK14-specific activity probe using recombinant protein technology*
**作者**: Garcia R et al.
**摘要**: 通过构建重组KLK14及其突变体，设计了一种基于荧光共振能量转移(FRET)的活性探针，用于高通量筛选KLK14抑制剂，为相关疾病的靶向治疗提供工具。
---
**备注**：以上内容为模拟文献摘要，实际研究中建议通过PubMed、Web of Science等平台检索关键词“KLK14 recombinant”获取真实文献，例如：
- **真实文献参考方向**：KLK14重组蛋白在卵巢癌生物标志物研究、皮肤屏障功能或阿尔茨海默病β-淀粉样蛋白降解中的文献可能存在。
**Background of KLK14 Recombinant Protein**
Kallikrein-related peptidase 14 (KLK14) is a serine protease belonging to the human tissue kallikrein family, which comprises 15 members (KLK1-KLK15). These enzymes play diverse roles in physiological and pathological processes, including skin desquamation, neural plasticity, inflammation, and cancer progression. KLK14 is encoded by the *KLK14* gene located on chromosome 19q13.4. a region densely clustered with other KLK genes. It is expressed in various tissues, such as the skin, prostate, and central nervous system, and is regulated by steroid hormones, cytokines, and epigenetic factors.
KLK14 exhibits trypsin-like enzymatic activity, cleaving substrates after arginine or lysine residues. It participates in proteolytic cascades, often interacting with other kallikreins and extracellular matrix components. Notably, KLK14 is implicated in pathological conditions, including psoriasis, neurodegenerative diseases, and cancers. In oncology, it is overexpressed in prostate, ovarian, and breast cancers, where it promotes tumor invasion, angiogenesis, and metastasis by activating protease-activated receptors (PARs) or modulating growth factor signaling.
Recombinant KLK14 protein is produced using engineered expression systems (e.g., *E. coli*, mammalian cells) to enable functional studies. Its recombinant form allows researchers to investigate substrate specificity, inhibitor interactions, and structural features. Purification often involves affinity tags (e.g., His-tag) and refolding steps to ensure enzymatic activity. Studies using recombinant KLK14 have highlighted its potential as a diagnostic biomarker or therapeutic target. For example, KLK14 inhibitors are being explored to block cancer-associated proteolysis, while its expression levels correlate with disease prognosis.
Despite progress, KLK14's full biological scope remains unclear. Ongoing research focuses on elucidating its role in tissue-specific pathways and diseases, leveraging recombinant protein tools to decode its mechanisms and therapeutic relevance.
×
